Author: Ravi Shankar

MaluDB™, MaluOS™, and MaluMail™ give organizations enterprise infrastructure for scalable agentic and generative AI applications, available in open-source and enterprise subscription editions

SCHAUMBURG, Ill., Oct. 20, 2026 (GLOBE NEWSWIRE) — Kinetic Seas Incorporated (OTCQB: KSEZ), an AI-focused software development company and a Certified Partner of the Claude Partner Network, today announced the commercial availability of three software platforms: MaluDB^™, MaluOS^™, and MaluMail^™. Together, the products expand the company’s enterprise AI technology portfolio, providing businesses with foundational infrastructure for building, deploying, and operating AI-enabled business applications safely and securely.

All three products are offered under a dual open-source and enterprise subscription model, giving developers, businesses, and technology partners access to the underlying technologies while creating commercial opportunities through enterprise subscriptions and related professional services.

Kinetic Seas also announced that it has filed federal trademark applications with the United States Patent and Trademark Office (USPTO) for the MALUDB, MALUOS, and MALUMAIL marks as part of its strategy to establish and protect a growing portfolio of proprietary software brands.

Three Platforms Supporting the AI-Enabled Enterprise

MaluDB^™ — Persistent Memory for Enterprise Artificial Intelligence

MaluDB^™ is a scalable AI memory and database platform that provides persistent, structured memory for AI applications and autonomous agents. Unlike memory systems that run on an individual desktop, MaluDB^™ is an enterprise-grade system built on PostgreSQL technology. It can be installed as standard packages on Linux and is fully integrated into the MaluOS^™ operating system.

MaluDB^™ delivers graph, vector, and relational search in a single platform built on PostgreSQL, one of the most durable and widely deployed databases in the enterprise. Organizations gain all three retrieval models without evaluating, procuring, and maintaining separate graph, vector, and relational database products, reducing the cost, risk, and review burden of bringing AI memory into production.

The lack of enterprise-grade persistent memory that can be shared across applications and AI agents has been a significant barrier to AI adoption. MaluDB^™ is designed to remove that barrier.

MaluOS^™ — The Enterprise Linux Operating System for Human and AI Partnerships

MaluOS^™ is a modular Linux operating system designed to bring together business applications, organizational knowledge, workflows, human users, and autonomous AI agents within a single secure platform.

MaluOS^™ supports organizations as they move beyond isolated AI tools toward integrated, AI-enabled business operations while maintaining data and AI sovereignty. The operating system is designed to securely manage enterprise applications, including traditional database, agentic AI, generative AI, and memory-first applications, using both frontier cloud models and open-weight local models.

MaluOS^™ also includes an application framework that allows independent developers to build their own AI-enabled applications and deploy them directly within the operating system. Applications built on the framework inherit MaluOS^™ services, including MaluDB^™ persistent memory, agent coordination, and security controls, so developers can focus on business functionality rather than infrastructure. Kinetic Seas expects the framework to support a growing ecosystem of third-party applications for the platform.

For organizations running open-weight models on their own hardware, MaluOS^™ provides a built-in queueing and routing system that manages inference requests across local models in a data center environment. This allows enterprises to deploy open-weight models at production scale, balancing workloads and directing requests to the appropriate model without relying on external cloud services.

MaluMail^™ — Enterprise Email and Communications Infrastructure

MaluMail^™ is a comprehensive email hosting and transmission platform built for AI-enabled applications in which AI agents must receive, process, and respond to email, while giving organizations granular control over the data AI agents can access within email.

Available as a hosted SaaS offering or as downloadable software for private deployment, MaluMail^™ enables organizations to operate their own email infrastructure while retaining flexibility over hosting, administration, and data management. The platform also provides a communications foundation that can be incorporated into broader enterprise applications and automated business workflows.

Solving the AI Deployment Problem for Business

A central principle behind Kinetic Seas’ AI products is reducing the obstacles companies face when deploying AI-centric applications.

Organizations can subscribe to cloud-hosted services or deploy the software within their own infrastructure. This approach supports businesses with differing requirements for data residency, privacy, customization, and information technology management. The platforms are designed to complement one another while remaining available as independent products.

“Artificial intelligence is rapidly evolving from a collection of individual tools into an integral component of how businesses operate,” said Edward Honour, Chairman and Chief Executive Officer of Kinetic Seas Incorporated. “We believe organizations will increasingly need three foundational capabilities: persistent memory that allows AI systems to retain and use knowledge, an operating environment that coordinates people and intelligent agents, and communications infrastructure that connects business activities. MaluDB, MaluOS, and MaluMail represent our approach to building that foundation.”

Honour continued, “Equally important is giving customers control over their technology. By offering both hosted and self-managed deployments, we can serve organizations that prioritize convenience as well as those that require direct control over their applications, infrastructure, and data.”

About Kinetic Seas Incorporated

Kinetic Seas Incorporated (OTCQB: KSEZ) is a technology company specializing in artificial intelligence, enterprise software development, and AI systems integration. The company develops software platforms and provides consulting, implementation, and technology services that help organizations adopt and deploy AI-enabled business solutions.

Kinetic Seas is Certified in the Claude Partner Network. The Claude Partner Network is how Anthropic works with the firms that put Claude into production for customers. Learn more at claude.com/partners.

Through its MaluDB^™ persistent memory platform, MaluOS^™ AI business operating system, MaluMail^™ email infrastructure platform, and related technology initiatives, Kinetic Seas is building an integrated portfolio of software solutions designed to support the next generation of intelligent business operations.

For more information, visit kineticseas.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding product adoption, future platform development, market opportunities, commercialization strategies, customer demand, the registration of pending trademark applications, and potential revenue opportunities. Words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “designed to,” “will,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include competition, technology development challenges, customer adoption, market conditions, financing requirements, intellectual property matters, including the possibility that pending trademark applications are not granted, and other factors described in the company’s filings with the U.S. Securities and Exchange Commission, including those described in the Risk Factors section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on May 29, 2026, and the Company’s subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report for the period ended June 30, 2026, filed on August 19, 2026, together with any other SEC filings, as amended or updated from time to time.

Forward-looking statements speak only as of the date of this release. Kinetic Seas undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

Copies of the Company’s filings with the SEC are available on the SEC’s website at www.sec.gov/edgar/searchedgar/companysearch.

Investor Relations Contact

Kinetic Seas Incorporated Schaumburg, Illinois Email: ir@kineticseas.com Website: kineticseas.com

LHV Group organised an investor meeting webinar on 20 October to give an overview of the 2026 Q3 financial results. An overview of the company’s progress was given by Mihkel Torim (CEO of LHV Group) and Meelis Paakspuu (CFO of LHV Group).

Recording of the investor meeting is available from link here.

Presentation is available here.

LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s key subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs approximately 1,200 people. The services of LHV Pank are used by over 517,000 customers, the II pillar pension funds managed by LHV have 104,000 active customers and LHV Kindlustus protects a total of 246,000 customers. LHV Bank Limited, a subsidiary of the Group, holds a banking licence in the United Kingdom and provides banking services to international financial technology companies, as well as loans to small and medium-sized enterprises.

Investor Relations
 Sten Hans Jakobsoo
 Head of Investor Relations and Corporate Development
 Email: stenhans.jakobsoo@lhv.ee

Communications
 Paul Pihlak
 Head of Communications
 Email: paul.pihlak@lhv.ee

SAN ANTONIO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT), a global enterprise AI infrastructure and solutions provider, today announced that it will release its third quarter 2026 financial results after market close on Monday, November 9, 2026. Gajen Kandiah, Chief Executive Officer, and Mark Marino, Chief Financial Officer, will host a conference call on Tuesday, November 10, 2026, at 8:30 a.m. ET to discuss its financial results.

Interested parties may access the conference call as follows:

To listen to the live webcast or access the replay following the webcast, please visit Rackspace Technology’s investor relations website at the following link: https://ir.rackspace.com/news-and-events/events-and-presentations.

To obtain a dial-in number, please pre-register at the following link: https://register-conf.media-server.com/register/BI0b0c05e627404fb498019571d04fbeb0.

Registrants will receive dial-in information and a PIN to access the live call.

About Rackspace Technology

Rackspace Technology® (NASDAQ: RXT) is the operator of the full enterprise AI stack from governed private cloud to AI inference and agents in production. With an Outcomes-as-a-Service model built on secure infrastructure, data foundations, and forward-deployed engineering, Rackspace delivers business results for regulated and mission-critical industries where governance, sovereignty, and uptime are non-negotiable. Learn more at www.rackspace.com.

Investor Relations Contact:
Investor Relations
ir@rackspace.com

Public Relations Contact:
Gracie LePere
publicrelations@rackspace.com

Drone-captured LiDAR, 3D progress monitoring and digital terrain modeling are designed to support construction visibility and recurring service relationships from earthworks through structural development

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech” or the “Company”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today outlined the capabilities and commercial strategy behind ZenaWorx, its drone-based construction monitoring software targeting AI data centers, infrastructure and public works projects. The ZenaWorx construction monitoring software combines aerial data collection with software-based site modeling and analysis to help construction teams understand conditions on the ground, track changes over time and compare construction progress against project plans. The platform is being developed through collaboration between ZenaTech’s enterprise SaaS and Drone as a Service (DaaS) divisions.

“AI infrastructure is built in the physical world, and every phase of that build depends on accurate, repeatable measurement,” said Shaun Passley, Ph.D., CEO of ZenaTech. “With ZenaWorx, we are combining our Drone as a Service field locations network with drone data and software to give customers a consistent view of their projects from earthworks through structural development. That turns what has traditionally been a one-time survey visit into an ongoing relationship that can span the full life of a multi-year project, and we believe it could be a meaningful recurring revenue opportunity as we focus on adding customers and scaling this service across our network.”

ZenaWorx is designed to function as construction progress monitoring software, turning drone-captured LiDAR (Light Detection and Ranging) data into three-dimensional representations of construction sites. By collecting data at successive stages of construction, the platform is intended to help project teams identify differences between measured conditions and planned designs.

Its planned capabilities and applications support the work of surveyors, engineers and construction managers by providing additional measured site information such as:

• 3D construction progress monitoring: Creating digital site models that help teams review structural and site development over time
• Digital terrain modeling: Representing ground elevations and surface conditions to support earthworks planning and monitoring
• Cut-and-fill measurement: Measuring the volumes of material removed or added during site preparation
• Grading assessment: Comparing measured elevations and slopes with engineering plans
• Drainage assessment support: Providing terrain information that helps qualified project professionals evaluate drainage conditions
• Repeat site comparisons: Using successive surveys to document changes and support standardized progress reporting

AI data center campuses can involve substantial land preparation, grading, drainage and phased construction, and ZenaWorx is being designed to give project teams visibility into each stage through repeat aerial data collection and software-based reporting. During initial earthworks, terrain models can support assessment of site elevations and material movement. As construction advances, updated 3D models are intended to help teams track physical progress and compare measured conditions against project plans. Underpinning this approach is a continuing record of site development, with customers able to access updated information at agreed intervals throughout a project.

ZenaWorx is being offered through ZenaTech’s Drone as a Service network, allowing customers to access drone construction monitoring services without purchasing and operating their own drone fleets. The service is designed to be subscription-based for repeat-service arrangements spanning the life of construction projects, and the platform’s terrain modeling and progress-monitoring capabilities are also intended to address commercial construction, and public works needs, including landfill earthworks and municipal infrastructure projects.

ZenaWorx was introduced in May 2026, and in August 2026 the Company announced its first paying customer for AI data center construction monitoring and the addition of beta-stage digital terrain modeling. Additional updates will be provided as ZenaWorx service and product advancements and customer milestones are achieved.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors and Media:
Linda Montgomery
ZenaTech
312-241-1415

Investors:
Michael Mason
CORE IR
investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities, including statements about the development, features, availability, pricing, commercialization and market adoption of ZenaWorx. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; ZenaTech’s ability to deliver products to the market as currently contemplated, including software platforms such as ZenaWorx; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; regulatory risks, including regulations governing drone operations; product development, validation and data quality and accuracy risks; customer adoption and recurring revenue opportunities; the competitive conditions of the industry; the ability to complete any contemplated acquisitions; market uncertainty; and applicable laws, regulations, and any amendments affecting the business of ZenaTech. Readers should not place undue reliance on forward-looking statements, which speak only as of the date of this release, and ZenaTech undertakes no obligation to update them except as required by law.

Board believes the current share price does not reflect the value of Host Digital’s contracted AI data center platform

NEW YORK, NY, Oct. 20, 2026 (GLOBE NEWSWIRE) — Host Digital Inc. (NYSE American: HOST) (“Host Digital” or the “Company”), a developer, owner, and operator of digital infrastructure for artificial intelligence (“AI”) and high-performance computing (“HPC”), today announced that its Board of Directors has unanimously authorized a share repurchase program under which the Company may repurchase up to $15 million of its outstanding common stock for up to one year.

The authorization reflects the Board’s confidence in Host Digital’s long-term strategy and gives the Company the flexibility to repurchase shares when it believes the market price does not reflect the value of its business, while continuing to prioritize the financing and delivery of its contracted data center projects.

Host Digital’s first project, Site I in northeast Oklahoma, is an energized facility with 55 megawatts (“MW”) of gross power and 43 MW of critical IT load. The site is leased under a 15-year take-or-pay agreement representing approximately $1.25 billion in base-term contracted revenue, with rent that increases 3% annually. The lease is expected to be supported by a backstop from a U.S.-based, investment-grade global technology company, and the Company is targeting delivery to its tenant in the first quarter of 2027.

Host Digital also continues to pursue the acquisition of a second energized and leased site in northeast Oklahoma from its sponsor, as previously disclosed.

“The Board authorized this program because we believe the market is undervaluing Host Digital and the assets it controls,” said Shawn Matthews, Chairman of the Board of Host Digital. “We see an opportunity to build long-term value per share by repurchasing stock at prices that do not appropriately reflect what this business is worth, in our view. We will weigh any repurchases against our project commitments and other uses of capital.”

“Our share price hasn’t changed the power available at Site I or the signed 15-year take-or-pay lease behind it,” said Harmol Samra, Host Digital’s Chief Executive Officer. “We’re targeting delivery in the first quarter of 2027, and our top priority remains financing, developing, and delivering our contracted projects. We’ll evaluate repurchases alongside those commitments and our other capital needs.”

In determining whether and when to repurchase shares, Host Digital will consider, among other factors, its liquidity and capital requirements, development expenditures, anticipated cash flows, alternative investment opportunities, the market price of its common stock, and prevailing market conditions.

The timing, method, price, and volume of any share repurchases will be at the Company’s discretion. Repurchases may be made through open market transactions, including pursuant to Rule 10b5-1 trading plans, privately negotiated transactions, or structured transactions arranged through investment banks, among other methods, in compliance with applicable securities laws and regulations, including Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934. The Company is not obligated to repurchase any specific number of shares and may modify, suspend, or discontinue the program at any time.

About Host Digital

Host Digital Inc. (NYSE American: HOST) primarily develops, acquires, owns, and operates institutional-quality data centers in the United States that support AI and HPC workloads. The Company focuses on RightScaled sites of 20 MW to 100 MW with existing or near-term access to power, leased under long-term contracts to strong or credit-enhanced counterparties. Host Digital seeks to own and control the real estate, power, and data center infrastructure at each site, and provides turnkey facilities where tenants select and deploy their own compute infrastructure and model layers. Host Digital is led by CEO Harmol Samra, formerly of PGIM, Starwood and ICONIQ, where they developed a 2.2GW data center platform with 82 sites worldwide, and Chairman Shawn Matthews, the former CEO of global investment bank Cantor Fitzgerald. For more information, visit www.hostdigital.ai.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the share repurchase program; whether, when, and to what extent shares may be repurchased; the expected timing of repurchases; the expected delivery of Site I; the Site I lease and its expected backstop; the potential acquisition of a second site; capital allocation, financing, liquidity, and development priorities; and the Company’s strategy, operations, and growth plans. These statements reflect current expectations and assumptions, not guarantees of future results. Actual outcomes may differ materially as a result of risks and uncertainties, including the availability of funds, future financing requirements, the Company’s ability to execute its development plans, market conditions, trading prices, contractual restrictions, and the risks described in the Company’s filings with the Securities and Exchange Commission. Readers should not place undue reliance on these statements, which speak only as of the date hereof. Host Digital undertakes no obligation to update forward-looking statements except as required by law.

Contacts

Media: Jessica Starman | jessica@elev8newmedia.com | 888-461-2233
Investors: Jason Assad | info@bridge-comms.com

Access the Moleculin CEO Corner here

HOUSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer.

In this episode of CEO Corner, Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the Company’s Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine (HiDAC) for patients with second-line relapsed or refractory acute myeloid leukemia (AML). The discussion highlights the completion of enrollment in Part A, encouraging interim efficacy results, Annamycin’s potential to address treatment resistance and cardiac safety concerns associated with conventional anthracyclines, and the anticipated full 90-patient Part A data readout in the first quarter of 2027. Mr. Klemp also outlines the next steps toward the pivotal Part B expansion and the broader potential for Annamycin across AML and other cancers treated with anthracyclines.

Access the CEO Corner on the Company’s website here.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, expected timing of the comprehensive Part A data readout in Q1 2027, the anticipated composition of the Part A population including the expected approximate 50/50 split between fit and unfit subjects, the potential for Part A data to support dose selection for Part B, and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Initial deployment targets select employees, with potential to expand across the company’s broader workforce

Bond’s enterprise customers include two of the three largest companies in the world and one of the three largest credit card companies

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today announced that an S&P 500 financial technology company has selected Bond to provide personal security services for its executives and at-risk employees.

The agreement marks another enterprise customer win for Bond, adding to its growing presence across multinational corporations, municipalities and other organizations. The initial deployment will cover a select group of executives and at-risk employees, with the potential to expand across the company’s broader workforce over time. Many of Bond’s enterprise customers start with an initial deployment covering executives, their family members and specific at-risk employees, but have returned for additional licenses after their initial deployment, offering the Bond service across the broader workforce including employees in other countries.

Innovation creates new opportunities to accomplish personal and corporate goals. Protecting employees outside of the corporate facilities has been an extremely expensive task, which companies can practically only achieve relative to a few executives. Bond changes that reality with its category defining AI-powered Preventative Personal Security platform. Employees face potential risks while traveling, commuting and going about their daily lives, driving demand for security that is not limited by location. When employees experience violent incidents, in their professional or private lives – it is both tragic and expensive for the employers, given that corporations cover medical costs, absenteeism due to injuries, potential churn and the cost of hiring and training replacements. Bond addresses this need through its AI-powered platform, combining on-demand technology with trained Personal Security Agents who respond by video within seconds from its 24/7 Command Centers to help identify potential threats, prevent incidents from escalating and coordinate emergency assistance when needed. A study by Ernst & Young (EY) found that organizations offering Bond to their employees can expect savings of approximately $181 per employee per year, mainly from reduced medical costs, higher productivity and lower absenteeism.

“Companies have historically invested heavily in protecting their facilities, but that protection often ends when employees leave the building,” said Doron Kempel, Founder and Chief Executive Officer of Our Bond. “Bond addresses this gap by providing preventative personal security wherever employees are. Being selected by an S&P 500 company to protect its executives is an important validation of our platform. We see this as a starting point, and our goal is to earn the opportunity to protect more of the company’s employees over time. This approach of ‘land and expand’ is common in the B2B space and aligns with a reality of introducing a new paradigm for which there is no precedent of usage and initial budget allocation.”

About Bond
Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond offers personal security to more people than any other company globally. Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.25 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC’s website at www.sec.gov. Our Bond, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
212-671-1020
OBAI@crescendo-ir.com

Recognition highlights Vlasic’s leadership of Vertex’s enterprise AI and data transformation and her commitment to developing the next generation of women in technology

KING OF PRUSSIA, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced that Sarah Vlasic, Vice President of Enterprise Data and AI Workforce Productivity, has been named a winner of the 2026 Info-Tech Women Leading IT Award by Info-Tech Research Group. This award recognizes exceptional women who are championing technology, fostering inclusive workplaces, and inspiring the next generation of IT leaders. 

Vlasic leads Vertex’s enterprise-wide data and AI transformation. She helped build the company’s AI operating model, which takes AI out of pilots and into daily work in product development, go-to-market, services, and customer engagement. She is also responsible for establishing the governance framework, so AI can be used responsibly at scale, and for modernizing Vertex’s data foundation to give leaders reliable, real-time insights.

“Sarah has been instrumental in turning our AI-first vision into how Vertex actually works every day,” said Aneel Jaeel, Chief Operations Officer at Vertex. “She pairs strategic clarity with a real commitment to her people, and this recognition reflects the impact she’s had across our business and the broader technology community.”

Outside of her day-to-day role, Vlasic mentors women in technology as an active member of Vertex’s WISE (Women in Search of Excellence) community. She currently serves on the University of Nevada, Las Vegas (UNLV) Lee Business School Corporate Advisory Board and has led Leadership Circles at the University of Colorado Boulder, helping develop the next generation of women leaders in business and technology through industry expertise, thought leadership, and professional development.

“I’m incredibly grateful and honored to receive this recognition from Info-Tech. While my name may be on the award, it truly reflects the hard work, passion, and dedication of the incredible teams that are turning AI from a concept into real business value at Vertex,” said Vlasic. “I’m fortunate to work alongside people who challenge what’s possible every day, embrace new ways of working, and continuously push us forward. I’m especially proud to help create opportunities for women in technology to grow, lead, and make a meaningful impact, and I’m proud to be part of an organization that supports and encourages that journey.”

The 2026 Info-Tech Award winners were selected from a competitive pool of hundreds of nominees. The full list of 2026 winners is available at infotech.com/events/infotech-awards.

About Info-Tech Research Group 
Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter. 

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform. Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com. 

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X. 

About Vertex  
Vertex is the Decision-to-Defense™ global indirect tax and compliance company. Vertex helps enterprises bring control to indirect tax and compliance across the full transaction lifecycle — from tax determination and e-invoicing through reporting, filing, and audit defense — to make outcomes easier to prove and improve over time. Trusted by more than 60% of the Fortune 500, Vertex combines decades of tax expertise, deep global tax and compliance knowledge, and embedded integrations to help organizations operate globally with confidence. With headquarters in North America and offices in South America and Europe, Vertex’s purpose is to ensure businesses and communities thrive through trusted transactions.

For more information, visit www.vertexinc.com or follow us on X and LinkedIn; or subscribe on YouTube.

Copyright © 2026 Vertex, Inc. All rights reserved. The information contained herein is intended for information purposes only, may change at any time in the future, and is not legal or tax advice. Any product direction and potential roadmap information is not a guarantee, may not be incorporated into any contract, and is not a commitment to deliver any material, code, or functionality. This information should not be relied upon in making purchasing, legal, or tax decisions. The development, release, and timing of any features or functionality described for Vertex’s products remains at the sole discretion of Vertex, Inc. Any statements in this release that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to various risks and uncertainties described in Vertex’s filings with the US Securities and Exchange Commission (“SEC”) that could cause actual results to differ materially from expectations. Vertex cautions readers not to place undue reliance on these forward-looking statements which Vertex has no obligation to update and which speak only as of their dates.

Vertex Company Contact: Simone Sonnier | Public Relations Manager | mediainquiries@vertexinc.com  

PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on November 4, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ326. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days

Intestinal exposure and tissue analyses strengthen the rationale for an oral, once-daily therapy targeting the ileum and colon

Phase 2b ASCENTRA-UC study enrolling; Phase 2a Crohn’s disease study being initiated

Denver, CO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, announced clinical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The findings connect targeted intestinal exposure to PALI-0008, the active metabolite of PALI-2108, with PDE4 target engagement, reduced intestinal inflammation and early clinical activity in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).

The new analyses build on previously reported Phase 1b results: a 47.5% reduction in mean endoscopic disease activity after 14 days in five patients with FSCD, and clinical response in all five patients in a separate UC cohort assessed after seven days. Palisade is enrolling the Phase 2b ASCENTRA-UC study and initiating a Phase 2a open-label study in Crohn’s disease.

“The strength of these findings is the connection between drug exposure at the site of disease, biological activity in intestinal tissue and early improvement on endoscopy,” said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. “In patients with longstanding fibrostenotic Crohn’s disease, most of whom were receiving biologic therapy, we observed endoscopic improvement within two weeks alongside reduced intestinal inflammation. Together with our UC findings, these results strengthen our confidence in advancing PALI-2108 as a once-daily oral treatment targeting both the ileum and colon. The exploratory tissue-remodeling signals also provide us with a compelling rationale to investigate its potential beyond inflammation.”

Rapid Endoscopic Improvement in Fibrostenotic Crohn’s Disease

Oral presentation OP003, presented by Florian Rieder, M.D., Cleveland Clinic, describes a Phase 1b open-label study in five patients with symptomatic ileal strictures and a mean disease duration of 15.4 years. Four of five patients were receiving concomitant biologic therapy. Patients received PALI-2108 once daily with food over 14 days, with titration to target doses of 20, 25 or 30 mg.

• Previously reported endoscopic activity: Mean Simple Endoscopic Score for Crohn’s Disease (SES-CD) decreased by 47.5%. Two of five patients (40%) achieved endoscopic response, and two of five (40%) achieved endoscopic remission, defined as an SES-CD of 0–2.
• Reduced intestinal inflammation: Mean fecal calprotectin decreased by 58.8% from baseline. Ileal tissue cAMP increased, consistent with PDE4 target engagement; exploratory analyses identified an inverse association between changes in tissue cAMP and fecal calprotectin.
• Evidence of tissue-level activity: Paired biopsy analyses showed reductions in inflammatory-cell populations. Exploratory single-nucleus RNA analyses identified reduced PDE4D expression in ileal enterocytes in three of four patients with paired sprovamples.
• Exploratory stricture observation: One stricture that could not be traversed by the endoscope at baseline was traversable at Day 14. This single-patient observation does not establish reversal of fibrosis.
• Favorable short-term tolerability: All reported adverse events were mild. No serious adverse events, treatment discontinuations, nausea, vomiting, diarrhea or headache were reported in this five-patient cohort.

Exploratory changes in collagen-degradation and macrophage-associated biomarkers were consistent with potential extracellular matrix remodeling and support further investigation of PALI-2108’s effects on fibrotic disease. These analyses do not establish an antifibrotic clinical benefit.

Early Clinical Activity and Histologic Improvement in Ulcerative Colitis

Moderated poster MP0844 builds on previously reported findings from five patients in the Phase 1b UC cohort, which evaluated titration to 30 mg twice daily. At the Day 7 assessment, all five patients achieved clinical response and two achieved clinical remission. Tissue analyses showed reductions in inflammatory-cell populations and improvements in histologic disease activity, alongside evidence of PDE4 target engagement.

These findings support ASCENTRA-UC, the ongoing Phase 2b study evaluating PALI-2108 at 15 mg and 30 mg once daily versus placebo in approximately 204 patients.

Intestinal Drug Exposure Supports Once-Daily Development

Moderated poster MP0564 further characterizes PALI-2108’s targeted delivery profile. In evaluated FSCD patients, mean intestinal tissue concentrations of active PALI-0008 were approximately 7.3-fold higher than peak plasma concentrations, with exposure demonstrated in the ileum, ascending colon and descending colon. Pharmacokinetic findings also supported sustained plasma exposure above the estimated PDE4 IC90, the concentration associated with 90% inhibition in vitro, over 24 hours at 30 mg once daily.

Together, these findings support the development of a once-daily oral therapy designed to concentrate PDE4 activity in intestinal tissue while providing sustained systemic exposure with a more gradual rise in plasma drug concentrations.

Transcriptomic Analyses Support Biomarker Development

Moderated poster MP0845 describes an exploratory analysis of approximately 3,000 transcriptomic samples from more than 15 studies. Composite signatures incorporating PDE4/cAMP signaling and inflammatory pathways improved separation of responder and non-responder phenotypes compared with PDE4 gene expression alone. The work supports further investigation of biomarkers that may help characterize treatment response; prospective predictive utility for PALI-2108 has not been established.

The UC and FSCD clinical findings are exploratory and derive from small, short-duration, open-label cohorts without placebo controls. They require confirmation in larger controlled studies. The studies do not establish comparative efficacy or safety, durable benefit, or reversal of intestinal fibrosis.

The presentations are available on the Publications page of the Company’s website.

About PALI-2108

PALI-2108 is an investigational oral PDE4 inhibitor prodrug designed for localized bioactivation in the terminal ileum and colon and being developed for once-daily dosing. Its active metabolite, PALI-0008, inhibits PDE4, increasing intracellular cAMP to modulate inflammatory signaling. Phase 1 studies have provided evidence of intestinal exposure, target engagement, favorable short-term tolerability and early clinical activity, supporting Phase 2 development in UC and Crohn’s disease. PALI-2108 has not been approved for any indication.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. Its lead program, PALI-2108, is advancing through Phase 2 development in inflammatory bowel disease.

For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PALI-2108, dosing levels and timing of key PALI-2108 development milestones such as regulatory submissions and approvals, trial enrollments and commencements and efficacy readouts, and the Company’s expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing, durability of effect or pharmacological properties, observed from preclinical or clinical trials (such as our Phase 1b findings) with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com